Loading people...
Karen Spilizewski is a Managing Director at RiverVest Venture Partners in Cleveland, Ohio, where she focuses on early-stage medical device investments, due diligence, and mentoring portfolio company executives. She joined the firm as a Vice President in 2008 to manage its Cleveland office, concurrently serving as a Vice President at BioEnterprise until 2020 before her promotion to Managing Director in 2023. Prior to her venture capital career, she spent nearly two decades at Avery Dennison Corporation directing research and business development for medical products, securing multiple patents. Spilizewski has held board director roles at several medical technology startups, including VentureMed Group, Standard Bariatrics, and Securus Medical Group, which was acquired by Boston Scientific Corporation. She earned an MBA, an MS in Macromolecular Science, and a BS in Biomedical Engineering, all from Case Western Reserve University.
Karen Spilizewski is a distinguished Vice President at RiverVest, a leading venture capital firm renowned for its strategic investments in the life sciences. Her expertise is instrumental in advancing RiverVest's mission to identify and nurture promising early-stage companies that are poised to make significant impacts in healthcare. At RiverVest, Karen is deeply involved in the entire investment lifecycle, from initial deal sourcing and rigorous due diligence to active portfolio management and strategic support for portfolio companies.
RiverVest's investment focus areas, where Karen's contributions are vital, primarily include biopharmaceuticals, medical devices, and other innovative healthcare technologies. The firm seeks out companies developing novel therapies, diagnostics, and medical solutions that address unmet medical needs and have the potential for substantial market growth. Karen's role involves assessing the scientific merit, market potential, and management teams of prospective investments, ensuring alignment with RiverVest's high standards and strategic objectives.
Karen's career background is characterized by a strong foundation in both science and business, providing her with a unique perspective in the complex world of life science venture capital. This dual expertise enables her to thoroughly evaluate the scientific rigor of new technologies while also understanding the commercial viability and strategic pathways for growth. Her analytical skills and deep industry knowledge are critical in navigating the intricate landscape of drug development, clinical trials, and regulatory approvals, which are inherent to the life science sector.
While specific notable investments led solely by a Vice President are often part of a broader team effort and not always publicly detailed, Karen Spilizewski plays a key role in the success of RiverVest's overall portfolio. Her work supports companies that are developing cutting-edge treatments for various diseases, improving patient outcomes, and shaping the future of medicine. She contributes to the strategic guidance provided to portfolio companies, helping them overcome challenges and achieve their milestones. Her dedication to fostering innovation and her commitment to the life sciences make her a valuable asset to RiverVest and the broader venture capital community, driving forward investments that promise to deliver transformative healthcare solutions.
Karen Spilizewski is a Vice President at RiverVest, a prominent venture capital firm specializing in life science investments. She is involved in deal sourcing, due diligence, and portfolio management for early-stage biopharmaceutical and medical device companies.
Karen Spilizewski, through her role at RiverVest, invests in early-stage life science companies. Her focus areas include biopharmaceuticals, medical devices, and other innovative healthcare technologies that address unmet medical needs.
Karen Spilizewski works as a Vice President at RiverVest, a leading venture capital firm dedicated to funding and supporting groundbreaking companies in the life sciences sector.
